Novavax Q4 net loss narrows
The company has posted loss from operations of $7.03m, compared to $14.15m for the comparable period in 2009. For the full year ended 31 December 2010, the company
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The Phase III multinational, randomized, double-blind, double-dummy, placebo-controlled trial enrolled 565 postmenopausal women with established osteoporosis in six countries. The study’s primary endpoint was the percent change in
The company is organizing two pivotal prospective, randomized, double-blinded, placebo-controlled, multicenter study Phase III trials CRUISE-1 and CRUISE-2. Each study expects to recruit around 300 patients, randomized equally